Literature DB >> 21253830

Barriers to, and strategies for, starting a long acting injection clinic in a community mental health center.

Dawn I Velligan1, Elisa Medellin, Meredith Draper, Natalie Maples, Albana Dassori, Troy A Moore, Linda Lopez.   

Abstract

As many as 50% of patients with schizophrenia do not take oral antipsychotic medications as prescribed, yet long acting injections are rarely utilized. Community agencies that serve this population are often over-burdened and poorly funded. There are negative attitudes on the part of both physicians and consumers about injections. Transportation and logistics are often problematic. We describe the unique opportunity provided by the need for bi-weekly or monthly injections to establish a recovery-oriented group around injection visits. Our approach discusses methods and resources to help overcome some of the common barriers by establishing advocates within the agency, establishing necessary infrastructure, providing education for consumers, providers, and staff, sharing information about successful outcomes with clinic staff and working through billing issues. We also recommend public advocacy on the part of the clinic and consumers to work with state funding sources to change regulations that may limit appropriate clinical care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253830     DOI: 10.1007/s10597-011-9389-6

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  18 in total

1.  Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.

Authors:  C E Adams; M K Fenton; S Quraishi; A S David
Journal:  Br J Psychiatry       Date:  2001-10       Impact factor: 9.319

2.  Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

Authors:  Dawn I Velligan; Francis Lam; Larry Ereshefsky; Alexander L Miller
Journal:  Psychiatr Serv       Date:  2003-05       Impact factor: 3.084

Review 3.  Relapse and rehospitalization: comparing oral and depot antipsychotics.

Authors:  Nina R Schooler
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

4.  Attitudes of psychiatrists toward antipsychotic depot medication.

Authors:  Stephan Heres; Johannes Hamann; Werner Kissling; Stefan Leucht
Journal:  J Clin Psychiatry       Date:  2006-12       Impact factor: 4.384

5.  Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

Authors:  J M Kane; E Aguglia; A C Altamura; J L Ayuso Gutierrez; N Brunello; W W Fleischhacker; W Gaebel; J Gerlach; J D Guelfi; W Kissling; Y D Lapierre; E Lindström; J Mendlewicz; G Racagni; L S Carulla; N R Schooler
Journal:  Eur Neuropsychopharmacol       Date:  1998-02       Impact factor: 4.600

6.  Antipsychotic medication adherence: is there a difference between typical and atypical agents?

Authors:  Christian R Dolder; Jonathan P Lacro; Laura B Dunn; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2002-01       Impact factor: 18.112

7.  Perception of depot antipsychotics by mental health professionals.

Authors:  Tim Lambert; Ann Brennan; David Castle; Deanna L Kelly; Robert R Conley
Journal:  J Psychiatr Pract       Date:  2003-05       Impact factor: 1.325

8.  Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

Authors:  Dawn I Velligan; Mei Wang; Pamela Diamond; David C Glahn; Desiree Castillo; Scott Bendle; Y W Francis Lam; Larry Ereshefsky; Alexander L Miller
Journal:  Psychiatr Serv       Date:  2007-09       Impact factor: 3.084

Review 9.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

10.  Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism.

Authors:  I E Babiker
Journal:  J Clin Psychiatry       Date:  1987-03       Impact factor: 4.384

View more
  10 in total

1.  Practical strategies for improving adherence to medication and outcomes.

Authors:  Dawn I Velligan; Martha Sajatovic
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

2.  Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability.

Authors:  Wagner F Gattaz; Ricardo Saracco-Alvarez; Claudiane Salles Daltio; Martinus T Van de Bilt; Jose Julian Ortegón; Sergio J Villaseñor-Bayardo; Mario Louzã; Helio Elkis; Bernardo Soares; Patricia Cabrera Jaramillo; Fabio Lawson; Leonardo Díaz-Galvis
Journal:  Neuropsychiatr Dis Treat       Date:  2020-09-10       Impact factor: 2.570

Review 3.  Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.

Authors:  Eduard Parellada; Miquel Bioque
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 4.  Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.

Authors:  Georgia L Stevens; Gail Dawson; Jacqueline Zummo
Journal:  Early Interv Psychiatry       Date:  2015-09-25       Impact factor: 2.732

5.  Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics.

Authors:  Ludovic Samalin; Marion Garnier; Candy Auclair; Pierre-Michel Llorca
Journal:  Int J Mol Sci       Date:  2016-11-19       Impact factor: 5.923

Review 6.  Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia.

Authors:  John M Kane; Joseph P McEvoy; Christoph U Correll; Pierre-Michel Llorca
Journal:  CNS Drugs       Date:  2021-10-11       Impact factor: 5.749

7.  Long-acting injectable antipsychotics in first-episode schizophrenia.

Authors:  Eduard Parellada; Dawn I Velligan; Robin Emsley; Werner Kissling
Journal:  Schizophr Res Treatment       Date:  2012-08-21

Review 8.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

9.  Discrepancy in Taiwanese psychiatrists' preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey.

Authors:  Chun-Hao Liu; Po-Hsin Tsai; Ching-Yen Chen
Journal:  Neuropsychiatr Dis Treat       Date:  2018-02-01       Impact factor: 2.570

10.  Hospitalizations and emergency room visits after initiation of long-acting injectable antipsychotics.

Authors:  Chelsie B Heesch; Troy A Moore; Cynthia A Gutierrez; Shuko Lee
Journal:  Ment Health Clin       Date:  2016-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.